Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 1,478 | 230 | 1,226 |
| Samples | 432 | 88 | 338 |
| Peptides | 275 | 62 | 221 |
Function
MAP2K3 · Mitogen-activated protein kinase kinase 3
The protein encoded by this gene is a dual specificity protein kinase that belongs to the MAP kinase kinase family. This kinase is activated by mitogenic and environmental stress, and participates in the MAP kinase-mediated signaling cascade. It phosphorylates and thus activates MAPK14/p38-MAPK. This kinase can be activated by insulin, and is necessary for the expression of glucose transporter. Expression of RAS oncogene is found to result in the accumulation of the active form of this kinase, which thus leads to the constitutive activation of MAPK14, and confers oncogenic transformation of primary cells. The inhibition of this kinase is involved in the pathogenesis of Yersina pseudotuberculosis. Multiple alternatively spliced transcript variants that encode distinct isoforms have been reported for this gene. [provided by RefSeq, Jul 2008].
Isoforms & Proteins
4 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 254 amino-acid changes on canonical ENST00000342679 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in MAP2K3 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in MAP2K3 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Gastrointestinal Stromal Tumour | 0/0 0% | 6/133 5% |
| Endometrial Carcinoma | 6/42 14% | 19/612 3% |
| Non-Small Cell Lung Carcinoma | 27/304 9% | 24/1390 2% |
| Thymic Epithelial Tumor | 0/0 0% | 1/39 3% |
| Oral Cavity Carcinoma | 1/54 2% | 0/0 0% |
| Melanoma | 4/210 2% | 32/1899 2% |
| Colorectal Carcinoma | 12/143 8% | 40/3239 1% |
| Small Cell Lung Carcinoma | 1/9 11% | 10/752 1% |
| Osteosarcoma | 3/45 7% | 0/166 0% |
| Neuroendocrine Tumour | 6/154 4% | 4/577 1% |
| Bladder Carcinoma | 1/58 2% | 12/956 1% |
| Squamous Cell Lung Carcinoma | 2/57 4% | 9/810 1% |
| Other Solid Cancers | 2/94 2% | 18/1515 1% |
| Thyroid Gland Carcinoma | 0/45 0% | 20/1592 1% |
| Gastric Carcinoma | 4/74 5% | 17/1809 1% |
| Acute Myeloid Leukemia | 1/90 1% | 0/0 0% |
| Esophageal Squamous Cell Carcinoma | 2/51 4% | 25/2550 1% |
| Cervical Carcinoma | 1/35 3% | 3/422 1% |
| Non-Cancerous | 0/104 0% | 7/830 1% |
| Hodgkins Lymphoma | 0/16 0% | 1/122 1% |
| Glioma | 0/52 0% | 15/2127 1% |
| Esophageal Carcinoma | 0/23 0% | 5/769 1% |
| Hepatocellular Carcinoma | 0/46 0% | 14/2210 1% |
| Plasma Cell Myeloma | 0/44 0% | 2/305 1% |
| Ovarian Carcinoma | 2/109 2% | 4/998 0% |
| Biliary Tract Carcinoma | 1/54 2% | 4/950 0% |
| Rhabdomyosarcoma | 0/33 0% | 1/171 1% |
| Kidney Carcinoma | 0/85 0% | 9/1862 0% |
| Burkitts Lymphoma | 1/32 3% | 0/196 0% |
| Head and Neck Carcinoma | 2/85 2% | 5/1574 0% |
Mutation Distribution
Where MAP2K3 is mutated · all tissues, split by cell line vs tissue
How many mutations in MAP2K3 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 1,478 mutations in MAP2K3
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|